Fig. 3: rhIL-7-hyFc enhances UCART33 expansion, persistence and anti-tumor efficacy in NSG mice engrafted with CD33+ U937^CBR-GFP cells in vivo.

a UCART33 are human T cells gene-edited to delete TRAC and then transduced with a lentivirus carrying a second-generation CAR construct targeting CD33 with a 4-1BB endodomain. NSG mice were injected with 5 × 10⁴ U937^CBR-GFP four days prior to administration of either 1 × 10⁶ UTD (untransduced T cells) or UCART33 cells, followed by rhIL-7-hyFc 10 mg/kg subcutaneously on days +1, +15, and +29 (n = 5/group for UTD, UTD + rhIL-7-hyFc, UCART33, n = 10 for UCART33 + rhIL-7-hyFc). b Survival analysis for each treatment group. p Values were calculated using two-sided Wilcoxon test. (UCART33 + rhIL-7-hyFc vs. UCART33 alone, p = 0.0015). c, d Serial tumor measurements by BLI. Data represent median ± 95% CI. Two-tailed p values were calculated using a linear mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences (UCART33 + rhIL-7-hyFc vs. UCART33 alone, p < 0.0001). e Quantitative flow cytometric analyses of UCART33 expansion in peripheral blood; also shown is a subgroup of mice (n = 5) that received UCART33 and rhIL-7-hyFc without prior tumor injection. Two-tailed p values were calculated using a linear mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences (UCART33 + rhIL-7-hyFc vs. UCART33 alone, p = 0.0053). Source data are provided as a Source data file. **p ≤ 0.01, ****p ≤ 0.0001.